Quick Answer
NRX Pharmaceuticals, Inc. reported Total Revenue of $1.23 million for fiscal year 2025.
NRX Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.23M | $0.00 | — | — | — | — |
| Revenue (ASC 606) | $1.23M | $0.00 | — | — | — | — |
| Net Income | -$28.62M -13.9% |
-$25.13M +16.7% |
-$30.15M +24.2% |
-$39.75M +57.3% |
-$93.06M -79.7% |
-$51.78M -12777.2% |
| Diluted EPS | — | — | — | -$0.60 +69.7% |
-$1.98 -31.1% |
-$1.51 |
| Total Assets | $12.96M +254.9% |
$3.65M -50.1% |
$7.32M -71.7% |
$25.82M -21.1% |
$32.73M +1012.9% |
$2.94M -90.8% |
| Cash and Equivalents | $7.80M +440.3% |
$1.44M -68.6% |
$4.59M -77.1% |
$20.05M -27.4% |
$27.61M | — |
| Stockholders Equity | -$15.94M +31.4% |
-$23.22M -97.9% |
-$11.73M -258.4% |
$7.41M -64.4% |
$20.81M +147.5% |
-$43.77M -803.8% |
| R&D Expense | $3.78M -39.1% |
$6.20M -53.6% |
$13.37M -21.5% |
$17.03M -15.9% |
$20.26M +90.7% |
$10.62M |
| Operating Income | -$16.22M +12.3% |
-$18.50M +33.5% |
-$27.84M +37.2% |
-$44.34M +61.7% |
-$115.80M -125.3% |
-$51.39M -7105.3% |
| Shares Outstanding | 31.73M +117.5% |
14.59M +73.9% |
8.39M -87.4% |
66.44M +13.0% |
58.81M +36.9% |
42.97M +1410.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $242.0K | — | — |
| Revenue (ASC 606) | September 30, 2025 | $242.0K | — | — |
| Net Income | September 30, 2025 | -$5.89M | -262.9% | +66.5% |
| Diluted EPS | March 31, 2024 | -$0.74 | +55.4% | -957.1% |
| Total Assets | September 30, 2025 | $15.00M | +236.1% | +210.0% |
| Cash and Equivalents | September 30, 2025 | $7.18M | +336.5% | +146.9% |
| Stockholders Equity | September 30, 2025 | -$25.75M | -36.8% | +27.7% |
| R&D Expense | September 30, 2025 | $1.43M | +133.9% | +44.8% |
| Operating Income | September 30, 2025 | -$4.02M | -33.2% | -7.9% |
| Shares Outstanding | September 30, 2025 | 27.68M | +143.4% | +42.2% |
- NRX Pharmaceuticals, Inc. reported Total Revenue of $1.23 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. reported Revenue (ASC 606) of $1.23 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. reported Net Income of -$28.62 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. showed a decrease of -13.9% in Net Income compared to the prior fiscal year.
- NRX Pharmaceuticals, Inc. reported Diluted EPS of $0.60 per share (loss) for fiscal year 2022.
- NRX Pharmaceuticals, Inc. showed an increase of +69.7% in Diluted EPS compared to the prior fiscal year.
- NRX Pharmaceuticals, Inc. reported Total Assets of $12.96 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. showed an increase of +254.9% in Total Assets compared to the prior fiscal year.
- NRX Pharmaceuticals, Inc. reported Cash and Equivalents of $7.80 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. showed an increase of +440.3% in Cash and Equivalents compared to the prior fiscal year.
- NRX Pharmaceuticals, Inc. reported Stockholders Equity of -$15.94 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. showed an increase of +31.4% in Stockholders Equity compared to the prior fiscal year.
- NRX Pharmaceuticals, Inc. reported R&D Expense of $3.78 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. showed a decrease of -39.1% in R&D Expense compared to the prior fiscal year.
- NRX Pharmaceuticals, Inc. reported Operating Income of -$16.22 million for fiscal year 2025.
- NRX Pharmaceuticals, Inc. showed an increase of +12.3% in Operating Income compared to the prior fiscal year.
- NRX Pharmaceuticals, Inc. reported Shares Outstanding of 31.73 million shares for fiscal year 2025.
- NRX Pharmaceuticals, Inc. showed an increase of +117.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: